Spectral Medical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EDT.TO research report →
Price Chart
About the company
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.
- CEO
- Chris Seto
- IPO
- 1996
- Employees
- 29
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on EDT.TO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $390.25M
- P/E
- -10.34
- Fwd P/E
- 66.50
- PEG
- 0.10
- P/S
- 151.91
- P/B
- -5.57
- EV/EBITDA
- -12.82
- Div Yield
- 0.00%
- Gross Margin
- -94.78%
- Op Margin
- -431.14%
- Net Margin
- -1391.98%
- ROE
- 51.23%
- ROIC
- 27.65%
Latest fiscal year · YoY change
- Revenue
- $2.44M+6.8%
- Gross Profit
- $-5,156,000-606.5%
- Op Income
- $-11,685,000
- Net Income
- $-47,692,000-209.6%
- EPS
- $-0.17-210.2%
- OCF Growth
- -8.0%
- FCF Growth
- -9.9%
- 52W High
- $1.76
- 52W Low
- $1.13
- 50D MA
- $1.37
- 200D MA
- $1.36
- Beta
- 0.21
- RSI (14)
- 42
- Avg Volume
- 55.62K
No earnings-call transcripts are available for EDT.TO yet.
- Free Float
- 70.5%
- Shares Outstanding
- 293.42M
- Float Shares
- 206.77M
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Perkins Investment Management, LLC | 10.00K | 0 |
Our EDT.TO coverage
Recent articles, reports, and earnings notes.
No research on EDT.TO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EDT.TO report →